ID   Jurkat E6.1 NF-kappaB::eGFP
AC   CVCL_WN96
DR   cancercelllines; CVCL_WN96
DR   Wikidata; Q94332818
RX   PubMed=25500904;
RX   PubMed=29029399;
RX   PubMed=31092850;
CC   Population: Caucasian.
CC   Characteristics: The eGFP reporter gene is under control of a NF-kappaB promoter element.
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0367 ! Jurkat E6.1
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 05-10-23; Version: 10
//
RX   PubMed=25500904; DOI=10.1038/srep07438;
RA   Ratzinger F., Haslacher H., Poeppl W., Hoermann G., Kovarik J.J.,
RA   Jutz S., Steinberger P., Burgmann H., Pickl W.F., Schmetterer K.G.;
RT   "Azithromycin suppresses CD4(+) T-cell activation by direct modulation
RT   of mTOR activity.";
RL   Sci. Rep. 4:7438-7438(2014).
//
RX   PubMed=29029399; DOI=10.18632/oncotarget.17615;
RA   Jutz S., Hennig A., Paster W., Asrak O., Dijanovic D., Kellner F.,
RA   Pickl W.F., Huppa J.B., Leitner J., Steinberger P.;
RT   "A cellular platform for the evaluation of immune checkpoint
RT   molecules.";
RL   Oncotarget 8:64892-64906(2017).
//
RX   PubMed=31092850; DOI=10.1038/s41598-019-43529-4;
RA   Humeniuk P., Geiselhart S., Battin C., Webb T.J., Steinberger P.,
RA   Paster W., Hoffmann-Sommergruber K.;
RT   "Generation of a Jurkat-based fluorescent reporter cell line to
RT   evaluate lipid antigen interaction with the human iNKT cell
RT   receptor.";
RL   Sci. Rep. 9:7426-7426(2019).
//